Skip to main
NPCE
NPCE logo

NeuroPace (NPCE) Stock Forecast & Price Target

NeuroPace (NPCE) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroPace Inc has demonstrated a significant improvement in the quality of life for patients using its RNS system, as evidenced by a meaningful increase of 3.2 points in the QOLIE-89 survey after one year of treatment. The company benefits from favorable macro trends, including a substantial increase in the number of Comprehensive Epilepsy Centers (CECs) and a 150% rise in the number of epileptologists per capita from 2012 to 2019, enhancing awareness and access to its products. Additionally, NeuroPace has reported impressive revenue growth, with a notable inflection in 2022, projecting a 75.5% increase from 2022 to 2024, which positions it favorably in the medical device sector.

Bears say

NeuroPace Inc. is facing ongoing financial challenges characterized by a consistent history of significant net losses, with no clear pathway to achieving or sustaining profitability in the near future. The company's need for additional capital may pose difficulties, leading to unfavorable funding terms that could necessitate cost-cutting measures and negatively impact its operations. Furthermore, existing financial obligations, including a restrictive term loan and uncertainty surrounding a distribution agreement, enhance the risks to its financial health and potential stock performance, compounded by challenges in market uptake and competition.

NeuroPace (NPCE) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroPace and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroPace (NPCE) Forecast

Analysts have given NeuroPace (NPCE) a Buy based on their latest research and market trends.

According to 5 analysts, NeuroPace (NPCE) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroPace (NPCE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.